Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2281-2291

  Gule, Maria K ^a   Chen, Yunyun ^a   Sano, Daisuke ^a   Frederick, Mitchell J ^a   Zhou, Ge ^a   Zhao, Mei ^a   Milas, Zvonimir L ^a   Galer, Chad E ^a   Henderson, Ying C ^a   Jasser, Samar A ^a   Schwartz, David L ^a,b   Bankson, James A ^a   Myers, Jeffrey N ^a   Lai, Stephen Y ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ANAPLASTIC CARCINOMA; ANAPLASTIC THYROID CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SURVIVAL TIME; THYROID CANCER; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD31; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOBLOTTING; IN SITU NICK-END LABELING; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954589240     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2762     Document Type: Article

References (46)

1. Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008;37:525-38, xi. (Pubitemid 351711678)
2. Ries L, Young J, Keel GE, Eisner MP, Lin YD, Horner M-J, editors SEER Survival monograph: Cancer survival among adults: U. S. SEER program, 1988-2001, patient and tumor characteristics. National Cancer Institute, SEER Program, NIH Pub No 07-6215, Bethesda, MD, 2007.
3. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 1999;16:64-9.
4. Chang HS, Nam KH, Chung WY, Park CS. Anaplastic thyroid carcinoma: a therapeutic dilemma. Yonsei Med J 2005;46:759-64. (Pubitemid 43085177)
5. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once-and twice-daily fractionation regimens. Cancer 2006;107:1786-92. (Pubitemid 44582947)
6. De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:1137-43. (Pubitemid 39440799)
7. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, et al. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck 2010;32:829-36.
8. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010;277:301-8.
9. Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005;27:684-94.
10. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000;166:475-80.
11. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64. (Pubitemid 26272076)
12. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000;10:349-57. (Pubitemid 30256865)
13. Dhar DK, Kubota H, Kotoh T, Tabara H, Watanabe R, Tachibana M, et al. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am J Surg 1998;176:442-7. (Pubitemid 29021544)
14. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995;11:1569-79.
15. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006;12:600-7. (Pubitemid 43166155)
16. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004;10:8594-602. (Pubitemid 40053427)
17. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 2005;4:632-40. (Pubitemid 40601845)
18. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008;93:4331-41. (Pubitemid 352789529)
19. Kim S, Park YW, Schiff BA, Doan DD, Yazici Y, Jasser SA, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res 2005;11:1713-21. (Pubitemid 40471832)
20. Ramirez MS, Bankson JA. A practical method for 2D multiple-animal MRI. J Magn Reson Imaging 2007;26:1162-6. (Pubitemid 47548183)
21. Weissleder R, Cheng HC, Marecos E, Kwong K, Bogdanov A. Jr. Noninvasive in vivo mapping of tumour vascular and interstitial volume fractions. Eur J Cancer 1998;34:1448-54. (Pubitemid 28370939)
22. Wen X, Jackson EF, Price RE, Kim EE, Wu Q, Wallace S, et al. Synthesis and characterization of poly (L-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent. Bioconjug Chem 2004;15:1408-15. (Pubitemid 39552032)
23. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr-related cancer 2009;16:17-44.
24. Lee DH, Lee GK, Kong SY, Kook MC, Yang SK, Park SY, et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 2007;60:881-4. (Pubitemid 47234434)
25. Ensinger C, Spizzo G, Moser P, Tschoerner I, Prommegger R, Gabriel M, et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann N Y Acad Sci 2004;1030:69-77. (Pubitemid 40378898)
26. Caponigro F, Formato R, Caraglia M, Normanno N, Iaffaioli RV. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 2005;17:212-7. (Pubitemid 40586159)
27. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78. (Pubitemid 43209104)
28. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S. Antiangiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 2009: CD005392.
29. Wells SA. Jr., Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72.
30. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 2009;19:1077-84.
31. Kim S. Animal models of cancer in the head and neck region. Clin Exp Otorhinolaryngol 2009;2:55-60.
32. Shibata MA, Shibata E, Morimoto J, Eid NA, Tanaka Y, Watanabe M, et al. An immunocompetent murine model of metastatic mammary cancer accessible to bioluminescence imaging. Anticancer Res 2009;29:4389-95.
33. Surguladze D, Steiner P, Prewett M, Tonra JR. Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging. Methods Mol Biol 2010;602:235-52.
34. Lee JJ, Foukakis T, Hashemi J, Grimelius L, Heldin NE, Wallin G, et al. Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. Thyroid 2007;17:289-301. (Pubitemid 46776132)
35. UKCCCR guidelines for the use of cell lines in cancer research. Br J Cancer 2000;82:1495-509.
36. Miettinen M, Franssila KO. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum Pathol 2000;31:1139-45.
37. Hoffmann S, Glaser S, Wunderlich A, Lingelbach S, Dietrich C, Burchert A, et al. Targeting the EGF/VEGF-R system by tyrosinekinase inhibitors-a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbeck's Arch Sur 2006;391:589-96. (Pubitemid 44657740)
38. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003;76:S36-42. (Pubitemid 39530314)
39. Hermans R, Meijerink M, Van Den Bogaert W, Rijnders A, Weltens C, Lambin P. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-andneck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1351-6. (Pubitemid 37443976)
40. Lehtiö K, Eskola O, Viljanen T, Oikonen V, Grönroos T, Sillanmäki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:971-82. (Pubitemid 38834289)
41. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003;89:1889-95. (Pubitemid 37533265)
42. Ansiaux R, Dewever J, Gregoire V, Feron O, Jordan BF, Gallez B. Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. Radiat Res 2009;172:584-91.
43. Bradley DP, Tessier JL, Checkley D, Kuribayashi H, Waterton JC, Kendrew J, et al. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR Biomed 2008;21:42-52. (Pubitemid 351227752)
44. Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Büchert M, et al. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 2009;1:5.
45. Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology 2010;256:441-9.
46. Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009;8:947-58.